This webcast discusses the key considerations to reduce risk for dry powder inhaler (DPI) and combination product development from early clinical trials through to scale-up. It provides insights for both novel and generic development programmes and helps answer the following questions:
- What are the options for dry powder inhaler (DPI) technology?
- What are the key factors influencing a combination product development?
- How will regulatory considerations affect the development strategy?
- How can I minimise the risk associated with scale up?
Andreas Meliniotis is Director of Device Development at Vectura, and leads the engineering and device development group based in Cambridge, UK. With over 15 years’ experience at Vectura, Andreas has led the design and development of several multi-dose DPIs as well as nebulisers and connected device technology.